Cipla launches generic Idiopathic Pulmonary Fibrosis drug Nintedanib in India
New Delhi: Pharma major Cipla on Tuesday said it has launched generic Nintedanib used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) under the brand name 'Nintib' in India. Available as 100 mg and 150 mg capsules, the launch marks another milestone in the company's decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people, Cipla said in a...
New Delhi: Pharma major Cipla on Tuesday said it has launched generic Nintedanib used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) under the brand name 'Nintib' in India.
Available as 100 mg and 150 mg capsules, the launch marks another milestone in the company's decade-long commitment to treat IPF, a rare lung disease that impacts ten in one lakh people, Cipla said in a statement.
Read also: Cipla gets USFDA nod for Dimethyl Fumarate DR Capsules to treat multiple sclerosis
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd